Relmada Therapeutics (RLMD) Other Non-Current Liabilities (2014 - 2018)

Relmada Therapeutics (RLMD) has 5 years of Other Non-Current Liabilities data on file, last reported at $4.2 million in Q2 2018.

• On a quarterly basis, Other Non-Current Liabilities rose 2285.31% year-over-year to $4.2 million in Q2 2018; TTM through Jun 2018 was $4.2 million, a 2285.31% increase from a year earlier, with the FY2018 full-year figure at $4.2 million, up 2285.31% from the prior year.
• Other Non-Current Liabilities for Q2 2018 stood at $4.2 million, up from $175853.0 in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for RLMD reached as high as $25.6 million in Q2 2014 and fell as low as $100000.0 in Q4 2014.
• Historically, Other Non-Current Liabilities has averaged $4.1 million across 5 years, with a median of $139421.0 in 2017.
• Across the five-year window, Other Non-Current Liabilities tumbled 93.63% in 2016 and jumped 2285.31% in 2018, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $100000.0 in 2014, then jumped by 13901.37% to $14.0 million in 2015, then plunged by 99.02% to $137078.0 in 2016, then gained by 28.29% to $175853.0 in 2017, then soared by 2285.31% to $4.2 million in 2018.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $4.2 million in Q2 2018, $175853.0 in Q2 2017, and $139421.0 in Q1 2017.